Abstract

Aim: To compare effects of 0.1% and 0.01% topical atropine eyedrops in myopic children.

Methods : This prospective randomized study was conducted on 80 eyes of 40 myopic children irrespective of age, type of myopia and amount of spherical equivalent correction. 40 eyes were subjected to 0.1% (Group A) and 40 to 0.01% topical atropine once at night (Group B). Follow-up was done at 3 months,6 months, 1 and 2 years. The effect of atropine on mean change in spherical equivalent, axial length, pupil diameter, keratometry and intra ocular pressure was recorded and compared between two groups. Any adverse effect as well as drop in near vision due to atropine was also noted.

Results: Mean age group studied in two groups was 10.5 years (range 5-13 years). The mean change in spherical equivalent after 2 years of atropine therapy was -0.35 ± 0.93 D in group A and -0.04 ± 0.57 D in group B (p < 0.05), the mean change in axial length was 0.27 ± 0.38 mm in group A and 0.05 ± 0.30 mm in group B (p > 0.05) and the mean change in pupil diameter was 1.05 ± 0.36 in group A and 0.84 ± 0.14 in group B (p < 0.05). 11 (55%) patients of group A and 6 (30%) patients of group B had difficulty while reading. However no statistical significant change was found in intraocular pressure and keratometric readings.

Conclusion: Both 0.1% and 0.01% topical atropine have comparable role in stabilization of myopia over 2 years. However, fewer visual side effects were noted with 0.01% atropine vs 0.1% atropine.

Keywords: Atropine; Children; Myopia; Spherical Equivalent

References

1. Pararajasegaram R. “Vision 2020- the right to sight: From strategies to action”. American Journal of Ophthalmology 128 (1999): 359-360.
2. Dolgin E. “The myopia boom”. Nature 519 (2015): 276-278.
3. Walline JJ., et al. “Interventions to slow progression of myopia in children”. Cochrane Database of System Review (2011): CD004916.
4. Mc Brien NA., et al. “How does atropine exert its anti - myopia effects”. Ophthalmic and Physiological Optics 33 (2013): 373-378.
5. McBrien NA., et al. “Expression of muscarinic receptor Subtypes in tree shrew ocular tissues and their regulation during the development of myopia”. Molecular Vision 15 (2009): 464-475.
6. Pan CW., et al. “Worldwide prevalence and risk factors for myopia”. Ophthalmic and Physiological Optics 32 (2012): 3-16.
7. Sun Y., et al. “Orthokeratologyto control myopia progression: a meta analysis”. PLoS One 10 (2015): e0124535.
8. Gwaizda J. “Treatment options for myopia”. Optometry and Vision Science 86 (2009): 624-628.
9. Fang PC., et al. “Prevention of myopia onset with 0.025% atropine in premyopic children”. Journal of Ocular Pharmacology and Therapeutics 26 (2010): 341-345.
10. Chia A., et al. “Atropine for the treatment of childhood myopia. Safety and efficacy of 0.5%, 0.1% and 0.01% doses (ATOM 2)”. Ophthalmology 119 (2012): 347-354.
11. Clark TY and Clark RA. “Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia”. Journal of Ocular Pharmacology and Therapeutics 31 (2015): 541-545.
12. Polling JR., et al. “Effectiveness study of atropine for progressive myopia in Europeans”. Eye 30 (2016): 998.
13. Yam JC., et al. “Low -concentration atropine for myopia progression (LAMP) study: a randomized, double –blinded, placebo-controlled trial of 0.055, 0.025% and 0.01% atropine eye drops in myopia control”. Ophthalmology 126 (2019): 113-124
14. Chia A., et al. “Effect of topical atropine on astigmatism”. British Journal of Ophthalmology 93 (2009): 799-802.
15. Lee CY., et al. “Effects of topical atropine on intraocular pressure and myopia progression: a prospective study”. BMC Ophthalmology 16 (2016): 114.
16. Kenndy RH. “Progression of myopia”. Transactions of the American Ophthalmological Society 93 (1995): 755-800.

Citation

Citation: Anand Aggarwal. “Comparative Evaluation of 0.1% and 0.01% Topical Atropine Eyedrops in Myopic Children".Acta Scientific Ophthalmology 4.3 (2021): 03-09.

Copyright

Copyright: © 2021 Anand Aggarwal. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.